Olmesartan medoxomil/amlodipine/hydrochlorothiazide

Drug Profile

Olmesartan medoxomil/amlodipine/hydrochlorothiazide

Alternative Names: CS-8635; Sevikar HCT; Sevikar Plus; Tribenzor

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antihypertensives; Benzothiadiazines; Dihydropyridines; Imidazoles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 01 Feb 2016 Sungkyunkwan University School of Medicine and Daiichi Sankyo initiate a clinical study for Hypertension in South Korea (ISRCTN51756760)
  • 03 Mar 2015 No recent reports on development identified - Phase-III for Hypertension in Puerto Rico, Russia and Ukraine (PO)
  • 01 Aug 2014 Daiichi Sankyo completes a phase III trial in Hypertension in South Korea (NCT01838850)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top